Rapamycin inhibits tamoxifen-induced endometrial proliferation in vitro as a pilot approach for endometrial protection in breast cancer
Abstract Tamoxifen, a common adjuvant therapy for hormone receptor-positive breast cancer, is associated with an increased risk of endometrial pathologies, such as hyperplasia, polyps, and carcinoma. This study investigates rapamycin, an mTOR inhibitor, as a potential novel strategy for preventing t...
Saved in:
Main Authors: | Akiko Nakamura, Yuji Tanaka, Tsukuru Amano, Akie Takebayashi, Akimasa Takahashi, Tetsuro Hanada, Yutaka Yoneoka, Shunichiro Tsuji, Takashi Murakami |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86586-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic Rapamycin Prevents Electrophysiological and Morphological Alterations Produced by Conditional Pten Deletion in Mouse Cortex
by: Jason S. Hauptman, et al.
Published: (2025-01-01) -
Machine learning Nomogram for Predicting endometrial lesions after tamoxifen therapy in breast Cancer patients
by: Cao Shaoshan, et al.
Published: (2025-01-01) -
MFAP5 inhibits the malignant progression of endometrial cancer cells in vitro
by: Liang Guanying, et al.
Published: (2024-12-01) -
Variation in human gut microbiota impacts tamoxifen pharmacokinetics
by: Yasmine Alam, et al.
Published: (2025-01-01) -
Prevalence of occult endometrial carcinoma in patients with endometrial intraepithelial neoplasia who underwent hysterectomy
by: Waraphon Thongsang, et al.
Published: (2025-01-01)